Genexine Inc (Genexine), formerly Genexine Co Ltd, is a clinical-stage biotechnology company that develops and commercializes immunotherapeutics and next-generation novel long-acting biologics. The company also develops therapeutic vaccines for incurable diseases and next-generation antibody fusion protein drugs. Its pipeline products include GX-H9, GX-G8, rhIL-7-hyFc, GX-G3, GX-G6, HPV DNA Vaccine and IL-7-hyFc. Genexine develops products for various therapeutic areas such as orphans, cancers and also immune disorders. The company uses hybrid Fc technology platform for the discovery of a wide range of differentiated agonistic protein therapeutics. It partners with other pharmaceutical companies for its research and development activities. The company has operations in the US and South Korea. Genexine is headquartered in Seongnam, South Korea
Headquarters
South Korea
Address
172, Magokjungang-ro, Gangseo-gu, Seoul, 13488
Website
genexine.com
Telephone
82 31 6283200
No of Employees
161
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
095700 (KDQ)
Revenue (2022)
$3.4M
-72.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-19.5%
(2022 vs 2021)
Market Cap*
$226.2M
Net Profit Margin (2022)
XYZ
-335.6%
(2022 vs 2021)
* As of and is in US$
Genexine Inc premium industry data and analytics
Products and Services
| Products |
|---|
| GX-I7: |
| Cancers |
| GX-188E: |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Genexine Inc | Dong-A Socio Holdings Co Ltd | Mezzion Pharma Co Ltd | Naturalendo Tech Co Ltd | CrystalGenomics Inc |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Seoul | Seoul | Seongnam | Seongnam |
| No. of Employees | 161 | 273 | 24 | 62 | 64 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Young-Jin Kim | Chairman | Executive Board | - | - |
| Neil K. Warma | Chief Executive Officer; Director; President | Executive Board | - | - |
| Sung June Hong | Director; Executive Vice President; Chief Financial Officer | Executive Board | - | - |
| Jungwon Woo | President; Director | Executive Board | - | - |
| Hyun-Jin Park | Executive Vice President - Corporate Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward